Midgard Finance drug data
Server Details
Obesity and incretin drug trials: weight loss by dose with its estimand, adverse events, catalysts
- Status
- Healthy
- Uptime
- 100.0% over the last 24 hours
- Last Tested
- Transport
- Streamable HTTP · MCP 2025-11-25
- URL
- ChatGPT
- –
- Claude
- Midgard Finance drug data
TDQS
Scored across 8 tools
Each tool has a distinct primary target: search, single-drug record, single-trial design, efficacy comparison table, adverse events, trajectory curve, catalysts, and news. The one soft boundary is between compare_efficacy, get_drug, and get_trajectory, which all surface efficacy numbers, but the descriptions make the distinction (multi-drug row-level table vs full record vs digitised curve) clear enough to choose correctly.
All eight tools follow the same verb_noun snake_case pattern (compare_efficacy, get_adverse_events, get_drug, get_trajectory, get_trial, list_catalysts, list_news, search_drugs). No camelCase or vague standalone verbs; the convention is entirely predictable.
Eight tools is well within the ideal 3-15 range for a domain-specific drug-data server. Each tool maps to a distinct workflow (search, detail, comparison, safety, trajectory, events, news), with no redundant entries padding the surface.
The surface covers the full research loop: discover drugs (search_drugs), inspect them (get_drug, get_trial), compare efficacy and safety, view curves, and track catalysts/news. Minor gaps exist—no browse-all-trials or list-all-drugs tool, and adverse events cannot be compared side-by-side the way efficacy can—but agents can work around these via search and per-drug calls.
Available Tools
8 toolscompare_efficacyCompare weight-loss efficacyCRead-onlyInspect
The extracted weight-loss table for the named drugs, joined to trial design, one row per arm and timepoint.
Rows are NOT collapsed to one number per drug. The corpus holds several doses, timepoints and estimands per trial, and picking a single winner per drug would mean choosing between them here, silently and on the caller's behalf. The comparison is theirs to make; this returns the rows and the labels needed to make it correctly.
Inputs: drugs (required), limit, metric, estimand, +1 more.
get_adverse_eventsGet adverse event ratesARead-onlyInspect
Extracted adverse-event rates for a named drug or trial, by arm, with the arithmetic that was checked.
drug is a molecule or a brand (tirzepatide or Zepbound). ae_type narrows to a kind of event,
every word of it found in the stored type: discontinuation_ae is the share who stopped the drug
because of an adverse event (quit over side effects), and the others include
discontinuation_ae_gi, nausea, vomiting, diarrhea, constipation, serious_ae, any_ae and death.
available_ae_types lists the types the named drug or trial holds. not_published names the
matching trials that hold no rows because their side-effect figures were never published, with
what the sponsor did say (REDEFINE 4, the CagriSema and tirzepatide head-to-head).
verification is carried through verbatim. It is the raw-count recomputation recorded when the
row was extracted ("997/2481 active = 40.18%"), and it is what lets a caller see that the
percentage was checked against the paper rather than copied from an abstract.
Inputs: drug, limit, trial, ae_type.
get_drugGet drug recordARead-onlyInspect
Full record for one drug, with its efficacy figures estimand-tagged and its page URL.
Matching goes slug, then exact name or brand, then substring, so "wegovy", "Wegovy HD" and "semaglutide-obesity" all land somewhere sensible without the caller knowing the slug scheme.
Inputs: name (required).
get_trajectoryGet weight-loss trajectoryBRead-onlyInspect
The digitised weight-loss curve for a drug: week-by-week points, plus per-dose series.
Returned with endpoint_pct and its estimand alongside the curve, because the endpoint marker
and the last plotted point are different quantities and the curve alone does not say which one
a reader is looking at.
Inputs: drug (required).
get_trialGet trial designARead-onlyInspect
One trial's design, by NCT number or by trial key (SURMOUNT-1, scale, redefine-1).
Inputs: identifier (required).
list_catalystsList upcoming catalystsARead-onlyInspect
Upcoming and recent readouts, approvals and trial starts across sponsors, oldest first.
For what comes next, pass from_date as today and pending_only=true, and kind="readout" for trial results; an event whose outcome is set has already happened.
from_date and to_date take YYYY-MM-DD, YYYY-MM, YYYY-Qn or YYYY. An event is dated as precisely as its sponsor guided it (a day, a month, a quarter or a year), and it is kept when that period overlaps the window, so an event guided to 2026-Q4 is still listed from 2026-11-10.
area: "obesity" or "diabetes". kind: "readout" (trial results, including cardiovascular outcomes trials), "regulatory" (submissions, decisions, coverage and launches), "trial_start" or "company" (earnings, conferences, investor days). pending_only: only events with no outcome recorded yet.
Inputs: area, kind, tier, limit, +3 more.
list_newsList latest newsARead-onlyInspect
The latest news the site's hubs print, newest first, with date, headline, source and page.
Use it for "what is new" and "latest announcement" questions. It holds the eight newest items
of each hub: obesity, Novo Nordisk and Eli Lilly. company matches the hub (Novo Nordisk,
Eli Lilly) or the drug's sponsor, drug a drug or brand in the item or its headline, query
a word in the headline (MASH, approval). kind on a Novo hub item says what it is (clinical,
regulatory, corporate, results, competitor: a rival's event that bears on Novo). An event older
than a hub's eight newest is not here: say so rather than guess. A headline's efficacy figure is
on the estimand the headline names, if any, and is not comparable with one on another.
Inputs: drug, limit, query, company.
search_drugsSearch drugsBRead-onlyInspect
Search the drug boards by free text and by field.
query also matches the other indications a molecule is pursuing, from the indications matrix
(MASH, CKD, sleep apnea, heart failure, CV outcomes, type 2 diabetes, and their trial names),
so "MASH" finds every cardiometabolic drug with a MASH programme and its status. sponsor
also matches a partner the matrix names (survodutide is licensed from Zealand Pharma to
Boehringer Ingelheim). Each result carries its indications row, or null for a drug the
matrix does not cover (cancer and immunology drugs, and MASH-only drugs, are not in it).
Inputs: area, limit, query, status, +1 more.
Tool Schema Changelog
Recent tool additions, removals, and schema changes observed during successful MCP inspections.
Loading tool schema changelog…
Related MCP Connectors
Evidence-graded reference on peptides and GLP-1 drugs: legal status, evidence, dosing, safety, cost.
GLP-1 phase-aware nutrition: muscle preservation, GI tolerance, taper protocols.
Studies and clinical trials for BPC-157, retatrutide, tirzepatide and 160+ peptides, with sources.
Cardiopulmonary exercise test (CPET) analysis: ventilatory thresholds, metrics and substrate use.
Related MCP Servers
- AlicenseNot gradedqualityNot gradedmaintenanceEnables computing composite glycemic load for multi-ingredient meals, modeling protein and fat attenuation of glucose spikes, and forecasting post-prandial fatigue and stable focus hours to guide meal and task scheduling.MIT
- AlicenseNot gradedqualityNot gradedmaintenanceEnables computational CPET analysis by calculating VE/VCO2 ventilatory equivalent slope, pulmonary dead space fraction, V-slope anaerobic threshold, and a cardiorespiratory efficiency index to support Zone 2 and threshold pacing directives.MIT
- AlicenseNot gradedqualityNot gradedmaintenanceEnables deterministic modeling of excess post-exercise oxygen consumption, bi-exponential recovery kinetics, cumulative oxygen debt and calorie burn, and post-workout fuel partitioning to guide hydration and refueling directives.MIT
- AlicenseNot gradedqualityBmaintenanceEnables modeling PGC-1alpha transcriptional induction, partitioning CaMK versus AMPK pathway signaling, and optimizing 80/20 polarized training for mitochondrial density.7MIT
Glama MCP Gateway
Add one secure layer between your agents and this server.